Likewise, a Notch4-neutralizing antibody reduced the tumorsphere-forming efficiency of cancer cells isolated from primary ductal carcinoma in situ, thus suggesting that Notch4 disruption would be therapeutically useful for the treatment of this cancer [143]. Here, NOTCH4 is linked to ductal breast carcinoma in situ.